Benefits
DashboardNot registered yet? Get a free account.
Sign UpNot registered yet? Get a free account.
Sign Up
You're about to leave our website and go to an external link. Are you sure?
Zydus Lifesciences Limited, is a listed public company incorporated on 15 May, 1995. It is classified as a public limited company and is located in Ahmedabad, Gujarat. It's authorized share capital is INR 172.50 cr and the total paid-up capital is INR 100.62 cr.
Zydus Lifesciences Limited's operating revenue range is Over INR 500 cr for the financial year ending on 31 March, 2023. It's EBITDA has increased by 27.96% over the previous year. At the same time, it's book networth has increased by 3.01%.
Read more
Buy Dashboard using Credits
This action will use 1 of your credits. Are you sure you want to go ahead?
Credits Balance:
0
** All rupee values in INR crores. Based on March 2024 numbers.
23.9%
65.36%
125.05%
15.23%
30.23%
17.12%
7.18
9.41
12.43
10.69
13.1
0.04
Buy Report or Plans
Company dashboard
Five year financials and ratios
Risk analysis
Interactive charts
All financials
All annual returns
MoA and AoA
Latest financials
Latest annual return
MoA and AoA
Five year financials and ratios
Shareholding and group structure
Litigation and more
Everything in financial report
Peers and financials
* GST not included
** Reports & MCA filings will be based on the latest available financials.
India
(57)
| State | Type | Address |
|---|
Locations on Map
Filter (4)
Severe Risk
Moderate Risk
Low Risk
Read more
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Networth | |||||
| Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Sales growth % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Expenses + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cost of goods | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Employee cost | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other costs | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other income | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Depreciation | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Exceptional items | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit before tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit - disc. ops | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Debt/Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Assets/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Liquidity + | |||||
| Current Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Quick Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest Coverage | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Performance | |||||
| Gross Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return + | |||||
| Return on Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROCE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return on Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROIC | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Efficiency + | |||||
| Days Payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Inventory | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Receivable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital | |||||
| Cash Conversion Cycle | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital Days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
ICICI Bank Limited
No. of Loans: 1
Total Amount : 1,500.0 cr
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Whole-time Director | Ganesh Narayan Nayak
Shareholder
|
00017481 | 7 years |
| Director | Apurva Shishir Diwanji | 00032072 | 9 years |
| Director | Mukesh Mangalbhai Patel
Shareholder
|
00053892 | 27 years |
| Director | Bhadresh Kantilal Shah | 00058177 | 6 years |
| Director | Pankaj Ramanbhai Patel
Shareholder
|
00131852 | 30 years |
| Managing Director | Sharvil Pankajbhai Patel
Shareholder
|
00131995 | 27 years |
| CFO | Nitinkumar Dalsukhray Parekh | <HIDDEN> | 10 years |
| Director | Shelina Pranav Parikh | 00468199 | 1 years |
| Director | Upasana Konidela | 02781278 | 2 years |
| Director | Monappa Arun Akhil | 09784366 | 2 years |
| CS | Dhaval Narendra Soni
Shareholder
|
<HIDDEN> | 6 years |
| Name | State / Country | Incorporation Year | Paidup Capital |
|---|---|---|---|
| Zynext Ventures USA LLC | United States | - | - |
| Zynext Ventures PTE. LTD | Singapore | - | - |
| Zydus Pharmaceuticals UK Limited | United Kingdom | - | - |
| DIALFORHEALTH UNITY LIMITED | Gujarat | 2005 | ₹ 5.0 L |
| DIALFORHEALTH GREENCROSS LIMITED | Gujarat | 2005 | ₹ 25.0 L |
| ZYDUS LANKA (PRIVATE) LIMITED | Sri Lanka | - | - |
| ZYDUS HEALTHCARE PHILIPPINES INC. | Philippines | - | - |
| ZYDUS INTERNATIONAL PRIVATE LIMITED | Ireland | - | - |
| ZYDUS NETHERLANDS B.V. | Netherlands | - | - |
| ZYDUS FRANCE, SAS | France | - | - |
| LABORATORIOS COMBIX S.L. | Spain | - | - |
| ETNA BIOTECH S.R.L. | Italy | - | - |
| ZYDUS PHARMACEUTICALS (USA) INC. | United States | - | - |
| ZYDUS HEALTHCARE (USA) LLC | United States | - | - |
| LM MANUFACTURING INDIA PRIVATE LIMITED | Gujarat | 2017 | ₹ 5.0 L |
| ZYDUS WORLDWIDE DMCC | United Arab Emirates | - | - |
| ZYDUS HEALTHCARE S.A. (PTY) LTD | South Africa | - | - |
| Alidac Pharmaceuticals SA Pty Ltd | South Africa | - | - |
| SCRIPT MANAGEMENT SERVICES (PTY) LTD | South Africa | - | - |
| ZYDUS NIKKHO FARMACEUTICA LTDA. | Brazil | - | - |
| Alidac Healthcare (Myanmar) Limited | Myanmar | - | - |
| Zydus Pharmaceuticals Mexico SA De CV | Mexico | - | - |
| ZYDUS PHARMACEUTICALS MEXICO SERVICES COMPANY SA DE C.V. | Mexico | - | - |
| Sentynl Therapeutics Inc. | United States | - | - |
| GERMAN REMEDIES PHARMACEUTICALS PRIVATE LIMITED | Gujarat | 2010 | ₹ 66.8 Cr |
| VIOLIO HEALTHCARE LIMITED | Gujarat | 2018 | ₹ 5.0 L |
| ZYDUS WELLNESS PRODUCTS LIMITED | Gujarat | 2019 | ₹ 218.8 Cr |
| LIVA INVESTMENT LIMITED | Gujarat | 2018 | ₹ 25.0 L |
| LIVA NUTRITIONS LIMITED | Gujarat | 2018 | ₹ 3.0 Cr |
| ZYDUS ANIMAL HEALTH AND INVESTMENTS LIMITED | Gujarat | 2018 | ₹ 1,774.4 Cr |
| Viona Pharmaceuticals (USA) Inc. | United States | - | - |
| ZYDUS PHARMACEUTICALS LIMITED | Gujarat | 2019 | ₹ 740.0 Cr |
| BIOCHEM PHARMACEUTICAL PRIVATE LIMITED | Gujarat | 2017 | ₹ 1.0 L |
| Zydus Wellness International DMCC | United Arab Emirates | - | - |
| ZYDUS VTEC LIMITED | Gujarat | 2020 | ₹ 302.5 Cr |
| ZYDUS STRATEGIC INVESTMENTS LIMITED | Gujarat | 2020 | ₹ 1.0 Cr |
| Zydus Therapeutics Inc. (USA) | United States | - | - |
| Zydus Wellness BD Pvt Ltd (Bangladesh) | Bangladesh | - | - |
| ZYDUS HEALTHCARE LIMITED | Gujarat | 1989 | ₹ 21.6 Cr |
| ZYDUS WELLNESS LIMITED | Gujarat | 1994 | ₹ 63.6 Cr |
| LM Manufacturing Limited | United Kingdom | - | - |
| Medsolutions (Europe) Limited | United Kingdom | - | - |
| LiqMeds Worldwide Limited | United Kingdom | - | - |
| LiqMeds Limited | United Kingdom | - | - |
| LiqMeds Lifecare Limited | United Kingdom | - | - |
| Zydus Pharmaceuticals (Canda) Inc | Canada | - | - |
| Zydus Lifesciences Global FZE | United Arab Emirates | - | - |
| Nesher Pharmaceuticals (USA) LLC | United States | - | - |
| ZyVet Animal Health Inc. | United States | - | - |
| Zydus Noveltech Inc. | United States | - | - |
| Hercon Pharmaceuticals, LLC | United States | - | - |
The incorporation date of ZYDUS LIFESCIENCES LIMITED is 15 May, 1995
The authorized share capital of ZYDUS LIFESCIENCES LIMITED is INR ₹ 172.5 Cr.
The paid-up capital of ZYDUS LIFESCIENCES LIMITED is INR ₹ 100.6 Cr.
The registered address of ZYDUS LIFESCIENCES LIMITED is Zydus Corporate Park,Scheme No. 63, Survey No. 536 Khoraj( Gandhinagar),Nr. Vaishnodevi Circ le, NA Ahmedabad Ahmedabad Gujarat - 382481
The CIN number of ZYDUS LIFESCIENCES LIMITED is L24230GJ1995PLC025878.
Expand
Delete
Collapse
See
details
